All In Biotech

Drug Trial Radar · NCT06460961

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jul 14, 2024

Primary completion

Jul 29, 2026

Study completion Jul 29, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy. There will not be any hypothesis testing in the study. As of Amendment 04 (effective date: 18-Dec-2025), there are no pharmacokinetic (PK) secondary outcome measures in this study.

Conditions

  • Neoplasm Metastasis

Interventions

  • MK-6837Biological

    IV Infusion

  • PembrolizumabBiological

    IV Infusion

  • Rescue MedicationsDrug

    Antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) administered per product label prior to MK-6837.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Cycle 1 (Up to approximately 21 days); each cycle is 21 days.
  2. Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 35 months
  3. Number of participants who discontinue study intervention due to an AETime frame: Up to approximately 35 months

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Atlantic Health System Morristown Medical Center ( Site 4001)

    Morristown, New Jersey

  • Providence Portland Medical Center ( Site 4002)

    Portland, Oregon

  • South Texas Accelerated Research Therapeutics (START) ( Site 4003)

    San Antonio, Texas

  • Westmead Hospital ( Site 1002)

    Westmead, New South Wales, Australia

  • The Alfred Hospital ( Site 1001)

    Melbourne, Victoria, Australia

  • Princess Margaret Cancer Centre ( Site 2001)

    Toronto, Ontario, Canada

  • Sheba Medical Center-ONCOLOGY ( Site 3001)

    Ramat Gan, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.